| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5811837 | Medical Hypotheses | 2014 | 5 Pages |
Abstract
RLC and KI were identified as potential prognostic parameters for superior disease control and overall survival after catumaxomab treatment. RLC may be used as a biomarker to indicate a suitable immune status for catumaxomab therapy. The predictive impact has to be confirmed in further studies.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Developmental Biology
Authors
Michael Alfred Ströhlein, Rolf Lefering, Dirk Rolf Bulian, Markus Maria Heiss,